The PALOMA-2 study evaluated palbociclib combined with letrozole as first-line therapy for patients with HR+, HER2− advanced breast cancer, a similar patient population to the subgroup analyzed here, which thus provides a baseline measure of efficacy for one of the current standard-of-care regimens (20, 21). Here, HR is linked to breast carcinoma.